Evidence map›Paper›PMID 29533668›Full record

ArticleMolecular pharmaceutics2018

Biomimetic Targeting of Nanoparticles to Immune Cell Subsets via Cognate Antigen Interactions.

Brian T Luk, Yao Jiang, Jonathan A Copp, Che-Ming J Hu, Nishta Krishnan, Weiwei Gao, Shulin Li, Ronnie H Fang, Liangfang Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Erythrocyte-Inspired Functional Materials for Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. CD4mBio · 2020
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Brian T LukDepartment of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States.
Yao JiangDepartment of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States.
Jonathan A CoppDepartment of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States.
Che-Ming J HuInstitute of Biomedical Sciences , Academia Sinica , Taipei 11529 , Taiwan.ORCID 0000-0002-0988-7029
Nishta KrishnanDepartment of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States.
Weiwei GaoDepartment of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States.
Shulin LiDepartment of Pediatric Research , MD Anderson Cancer Center , Houston , Texas 77030 , United States.
Ronnie H FangDepartment of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States.
Liangfang ZhangDepartment of NanoEngineering and Moores Cancer Center , University of California, San Diego , La Jolla , California 92093 , United States.ORCID 0000-0003-0637-0654
University of California San Diego · USInstitute of Biomedical Sciences, Academia Sinica · TWThe University of Texas MD Anderson Cancer Center · US

Funding

Pathway Specific Functional Biomarkers for the Early Detection of Liver CancerU01CA230690 · NCI · GEORGE WASHINGTON UNIVERSITY · PI MISHRA, LOPA, SHETTY, KIRTI · 2018 to 2022
$3.4M
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma MetastasisR01CA200574 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LI, SHULIN, ZHANG, LIANGFANG · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA200574NCI NIH HHS U01 CA230690
6 · The paper itself

Abstract

Within the body, cellular recognition is mediated in large part by receptor-ligand interactions that result from the surface marker expression of the participant cells. In the case of immune cells, these interactions can be highly specific, enabling them to carry out their protective functions in fighting off infection and malignancy. In this work, we demonstrate the biomimetic targeting of antigen-specific immune cell populations by using nanoparticles functionalized with natural membrane derived from cells expressing the cognate antigen. Using red blood cell (RBC)-specific B cells as a model target, it is shown that RBC membrane-coated nanoparticles exhibit enhanced affinity compared with control nanoparticles. The concept is further demonstrated using murine models of alloimmunity and autoimmunity, where B cells elicited against RBCs can be positively labeled using the biomimetic nanoparticles. This strategy for antigen-specific immune cell targeting may have utility for the detection and treatment of various autoimmune conditions, and it may additionally have implications for the prevention of immune cell malignancies.

Indexed as

AnimalsBiomimetic MaterialsBiomimeticsErythrocytesFemaleMaleMiceMice, Inbred C57BLNanoparticlesNanotechnologyautoimmune diseaseB cellbiointerfacingbiomimetic nanotechnologylymphomamembrane-coated nanoparticle

Identifiers

PMID29533668
PMCPMC6123265
OpenAlexW2792904949

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.